Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Präsentationen zeigen Fortschritte in BioNTechs spätklinischen Programmen im Bereich Lungenkrebs und unterstreichen das Potenzial des differenzierten Unternehmensportfolios, welches Immunmodulatoren,...
-
Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated portfolio spanning immunomodulators, antibody-drug conjugates,...
-
Das neue Gebäude ist Teil einer Investition in Höhe von CHF 1,4 Milliarden in den Standort und unterstreicht das Engagement von Roche in der Schweiz und für den Life Sciences Cluster Basel.Das...
-
The new building is part of a CHF 1.4 billion site investment, reinforcing Roche’s commitment to Switzerland and the Basel life sciences clusterThe Institute of Human Biology (IHB) enables scientists...
-
Pelareorep treatment drives coordinated immune activation and tertiary lymphoid structure formation Translational data suggest potential to boost response to immunotherapy and targeted therapy in...
-
BLACKHAWK, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Vesicor Therapeutics, Inc., a San Gabriel, California-based early development stage biotechnology corporation focused on the development of...
-
Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with advanced non-small cell lung cancer (NSCLC) treated with...
-
With the addition of 2,176 NVIDIA Blackwell GPUs, Roche now operates the pharmaceutical industry’s largest announced hybrid-cloud AI factory, totaling more than 3,500 GPUs. The new computational...
-
Orlando, Florida, March 12, 2026 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) concluded its 2026 MDA Clinical & Scientific Conference yesterday, convening over 2,400 attendees...
-
NEW YORK, March 11, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the appointment of...